Claudia Wellbrock

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4227594/claudia-wellbrock-publications-by-year.pdf
Version: 2024-04-20

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59 papers	5,236 citations	31 h-index	61 g-index
61 ext. papers	5,928 ext. citations	10.9 avg, IF	5.87 L-index

#	Paper	IF	Citations
59	Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma. *Cancers*, **2021**, 13,	6.6	1
58	Cooperative behaviour and phenotype plasticity evolve during melanoma progression. *Pigment Cell and Melanoma Research*, **2020**, 33, 695-708	4.5	9
57	Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival. *Pigment Cell and Melanoma Research*, **2020**, 33, 74-85	4.5	4
56	Phenotype plasticity as enabler of melanoma progression and therapy resistance. *Nature Reviews Cancer*, **2019**, 19, 377-391	31.3	125
55	A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF /AXL melanoma. *Pigment Cell and Melanoma Research*, **2019**, 32, 280-291	4.5	20
54	Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing. *Oncogene*, **2018**, 37, 3166-3182	9.2	51
53	Targeting invasive properties of melanoma cells. *FEBS Journal*, **2017**, 284, 2148-2162	5.7	26
52	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. *Journal of Experimental Medicine*, **2017**, 214, 1691-1710	16.6	51
51	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. *Cancer Discovery*, **2017**, 7, 832-851	24.4	31
50	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. *Cell Reports*, **2017**, 20, 1818-1829	10.6	128
49	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. *EMBO Molecular Medicine*, **2017**, 9, 1011-1029	12	49
48	Overcoming resistance to BRAF inhibitors. *Annals of Translational Medicine*, **2017**, 5, 387	3.2	64
47	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). *Annals of Translational Medicine*, **2017**, 5, 390-390	3.2	78
46	Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth. *Oncotarget*, **2017**, 8, 32946-32959	3.3	32
45	Melanoma and the Microenvironment--Age Matters. *New England Journal of Medicine*, **2016**, 375, 696-8	59.2	2
44	Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. *Clinical Cancer Research*, **2016**, 22, 5966-5970	12.9	30
43	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. *Cancer Cell*, **2016**, 29, 270-284	24.3	149

42	The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. *Frontiers in Cell and Developmental Biology*, **2016**, 4, 33	5.7	67
41	Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies. *EMBO Molecular Medicine*, **2015**, 7, 1087-9	12	8
40	MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. *Molecular Cancer Therapeutics*, **2015**, 14, 1236-46	6.1	26
39	Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. *Pigment Cell and Melanoma Research*, **2015**, 28, 390-406	4.5	138
38	Differentiation of THP1 Cells into Macrophages for Transwell Co-culture Assay with Melanoma Cells. *Bio-protocol*, **2015**, 5,	0.9	29
37	MAPK pathway inhibition in melanoma: resistance three ways. *Biochemical Society Transactions*, **2014**, 42, 727-32	5.1	18
36	Heterogeneous tumor subpopulations cooperate to drive invasion. *Cell Reports*, **2014**, 8, 688-95	10.6	135
35	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. *Molecular Cancer*, **2014**, 13, 154	42.1	2
34	Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells. *Journal of Cell Science*, **2014**, 127, 1346-56	5.3	29
33	The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF□*Cancer Discovery*, **2014**, 4, 1214-1229	24.4	139
32	Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. *Journal of the National Cancer Institute*, **2013**, 105, 33-46	9.7	78
31	The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. *Immunology*, **2010**, 129, 610-9	7.8	8
30	BRAF as therapeutic target in melanoma. *Biochemical Pharmacology*, **2010**, 80, 561-7	6	126
29	STAT5 contributes to antiapoptosis in melanoma. *Melanoma Research*, **2008**, 18, 378-85	3.3	26
28	Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. *PLoS ONE*, **2008**, 3, e2734	3.7	200
27	Melanoma biology and new targeted therapy. *Nature*, **2007**, 445, 851-7	50.4	1018
26	The oncogenic epidermal growth factor receptor variant Xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions. *Cancer Research*, **2006**, 66, 3145-52	10.1	26
25	FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. *EMBO Journal*, **2006**, 25, 3078-88	13	150

24	Melanoma Development and Pigment Cell Transformation **2006**, 247-263		
23	STAT5 contributes to interferon resistance of melanoma cells. *Current Biology*, **2005**, 15, 1629-39	6.3	52
22	Activating mutations in the extracellular domain of the melanoma inducing receptor Xmrk are tumorigenic in vivo. *International Journal of Cancer*, **2005**, 117, 723-9	7.5	21
21	Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. *Journal of Cell Biology*, **2005**, 170, 703-8	7.3	138
20	The RAF proteins take centre stage. *Nature Reviews Molecular Cell Biology*, **2004**, 5, 875-85	48.7	922
19	The Brn-2 transcription factor links activated BRAF to melanoma proliferation. *Molecular and Cellular Biology*, **2004**, 24, 2923-31	4.8	102
18	Identification of a second egfr gene in Xiphophorus uncovers an expansion of the epidermal growth factor receptor family in fish. *Molecular Biology and Evolution*, **2004**, 21, 266-75	8.3	35
17	V599EB-RAF is an oncogene in melanocytes. *Cancer Research*, **2004**, 64, 2338-42	10.1	298
16	MITF-M plays an essential role in transcriptional activation and signal transduction in Xiphophorus melanoma. *Gene*, **2003**, 320, 117-26	3.8	18
15	Melanoma development and pigment cell transformation in xiphophorus. *Microscopy Research and Technique*, **2002**, 58, 456-63	2.8	25
14	Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. *Oncogene*, **2002**, 21, 1668-78	9.2	44
13	Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. *Journal of Biological Chemistry*, **2002**, 277, 6443-54	5.4	67
12	Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. *Cancer Research*, **2002**, 62, 4820-8	10.1	59
11	Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. *Molecular and Cellular Biology*, **2001**, 21, 2324-36	4.8	161
10	Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. *Journal of Biological Chemistry*, **2001**, 276, 3333-40	5.4	38
9	Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells. *FEBS Journal*, **2000**, 267, 3513-22		26
8	Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc. *FEBS Journal*, **1999**, 260, 275-83		30
7	A two-step selection approach for the identification of ligand-binding determinants in cytokine receptors. *Analytical Biochemistry*, **1999**, 268, 179-86	3.1	

6	PI3-kinase is involved in mitogenic signaling by the oncogenic receptor tyrosine kinase Xiphophorus melanoma receptor kinase in fish melanoma. *Experimental Cell Research*, **1999**, 251, 340-9	4.2	21
5	Activation of the Xmrk proto-oncogene of Xiphophorus by overexpression and mutational alterations. *Oncogene*, **1998**, 16, 1681-90	9.2	29
4	Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. *Oncogene*, **1998**, 16, 3047-56	9.2	31
3	Receptor tyrosine kinase Xmrk mediates proliferation in Xiphophorus melanoma cells. *International Journal of Cancer*, **1998**, 76, 437-42	7.5	23
2	Signal transduction by the oncogenic receptor tyrosine kinase Xmrk in melanoma formation of Xiphophorus. *Pigment Cell & Melanoma Research*, **1997**, 10, 34-40		17
1	DGAT1 is a lipid metabolism oncoprotein that enables cancer cells to accumulate fatty acid while avoiding lipotoxicity		1